• Molecular NameKetoconazole
  • Synonym2%; Ketocanazole; Ketoconazol; Ketoconazol [INN-Spanish]; ketoconazole; Ketoconazole [Usan:Ban:Inn:Jan]; Ketoconazolum [INN-Latin]
  • Weight531.44
  • Drugbank_IDDB01026
  • ACS_NO65277-42-1
  • Show 3D model
  • LogP (experiment)4.34
  • LogP (predicted, AB/LogP v2.0)3.95
  • pka4.4
  • LogD (pH=7, predicted)3.85
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.68
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.07
  • No.of HBond Donors0
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds7
  • TPSA69.06
  • StatusFDA approved
  • AdministrationOral, topical
  • PharmacologyA synthetic antifungal drug used to prevent and treat skin and fungal infections, especially in immunocompromised patients such as those with AIDS.
  • Absorption_value75.0
  • Absorption (description)Ketoconazole is readily but incompletely absorbed after oral administration
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)2.4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)Plasma : whole blood ratio, 1.6.
  • MetabollsmExtensively metabolised to inactive metabolites.
  • Half life3.3 h
  • ExcretionAbout 13% of a dose is excreted in the urine in 4 days and 57% is eliminated in the faeces in the same period.
  • Urinary Excretion<1
  • Clerance8.4 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)LD50=86 mg/kg
  • LD50 (mouse)N/A